Faculty Opinions recommendation of Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

2013 ◽  
Author(s):  
Juan-Carlos Kaski ◽  
Amelia Carro
Keyword(s):  
Atrial Fibrillation ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Efficacy And Safety ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs ◽  
Indirect Comparisons

scholarly journals The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients

Medicine ◽  
2019 ◽  
Vol 98 (48) ◽  
pp. e18205
Author(s):  
Yi-yue Gui ◽  
Song Zou ◽  
Wen-long Yang ◽  
Shen-zhen Gong ◽  
Zhi-fu Cen ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Renal Function ◽  
Oral Anticoagulant ◽  
Efficacy And Safety ◽  
New Oral Anticoagulant ◽  
The Impact

Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease

2016 ◽  
Vol 23 (19) ◽  
pp. 2055-2069 ◽  
Author(s):  
Tatjana S. Potpara ◽  
Vera Jokic ◽  
Nikolaos Dagres ◽  
Torben B. Larsen ◽  
Deirdre A. Lane ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vitamin K ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Anticoagulant Drugs

scholarly journals NEW ORAL ANTICOAGULANT DRUGS IN ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME

2013 ◽  
pp. 42-48
Author(s):  
Aleksandra Novaković ◽  
Tatjana Divac ◽  
Ivan Stojanović ◽  
Predrag Milojević ◽  
Dragoslav Nenezić
Keyword(s):  
Atrial Fibrillation ◽  
Acute Coronary Syndrome ◽  
Oral Anticoagulant ◽  
Coronary Syndrome ◽  
New Oral Anticoagulant ◽  
Anticoagulant Drugs

scholarly journals Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Jorge Ferreira ◽  
Daniel Ferreira ◽  
Miguel Viana-Baptista ◽  
Paulo Bettencourt ◽  
Rui Cernadas ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Real World ◽  
Stroke Prevention ◽  
Oral Anticoagulant ◽  
Dabigatran Etexilate ◽  
Direct Thrombin Inhibitor ◽  
Thrombin Inhibitor ◽  
Joint Effort ◽  
Nonvalvular Atrial Fibrillation ◽  
New Oral Anticoagulant

Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.

Sign in / Sign up

Export Citation Format

Share Document